Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Bone Loss in Prostate Cancer Patients on ADT
NCT00063609Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in osteoporosis comparing Zoledronic Acid with Placebo (2 arms). Primary endpoint: Percent change in bone mineral density of the lumbar spine (L2-L4) at 1 year. Started Apr 2003; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00063609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063609.